On June 2, 2022 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, reported that it will participate in the Virtual Investor Innovation in Oncology Event on Thursday, June 9, 2022 at 11:00 AM ET (Press release, Xenetic Biosciences, JUN 2, 2022, View Source [SID1234615488]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For the roundtable discussion, Jeffrey F. Eisenberg, Chief Executive Officer and Curtis A. Lockshin, PhD, Chief Scientific Officer of Xenetic Biosciences will be joined by Allan Tsung, MD, Scientific Advisor to the Company, Director of Surgical Oncology at the Ohio State James Comprehensive Cancer Center and Co-Director of the Gastrointestinal Clinical Trials portfolio, and recently appointed Chair of the Department of Surgery at the University of Virginia School of Medicine and Director of the Cancer Therapeutics program at the UVA Comprehensive Cancer Center. As part of the event, the Company and Dr. Tsung will discuss the Company‘s recently licensed DNase-based oncology platform, the role of Neutrophil Extracellular Traps ("NETs") in cancer and the use of DNase in targeting NETs, and the potential broad utility of the platform for the treatment of high-value oncology indications where there remains significant unmet need.
In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible during the event.
A live video webcast of the Virtual Investor Innovation in Oncology Event will be available on the Events page in the Investors section of the Company’s website (xeneticbio.com) and archived for 90 days.